Aurobindo Pharma Limited has received regulatory clearance from the US Food and Drug Administration (USFDA) for a combination drug used in diabetes management. The approval enables the company to manufacture and market the product in the United States, marking a development in its generics portfolio and US business operations.
Aurobindo Pharma has secured final approval from the USFDA for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in multiple dosage strengths.
The approved formulation is therapeutically equivalent to the reference listed drug Xigduo XR, originally developed by AstraZeneca. The drug is prescribed to improve glycaemic control in adults with type 2 diabetes, alongside diet and exercise.
The company has indicated that the product will be manufactured at its subsidiary facility and is expected to be launched in the US market in the near term.
This addition strengthens the company’s presence in the anti-diabetic segment, which remains a key therapeutic area in global pharmaceutical markets.
The approved product has an estimated market size of approximately USD 514 million for the twelve months ending February 2026, based on industry data.
Aurobindo Pharma is also among the early applicants for this product, making it eligible for 180 days of shared generic exclusivity. This period may provide a temporary advantage in terms of market entry and competition.
As of March 31, 2026, the company holds a total of 579 ANDA approvals from the USFDA, including both final and tentative approvals.
The company continues to expand its portfolio across therapeutic areas such as anti-diabetics, cardiovascular, antibiotics and central nervous system treatments, supported by its manufacturing and research capabilities.
Shares of Aurobindo Pharma Limited were trading at ₹1,341.00 as of 2:14 PM on 8 April 2026, up by ₹11.00 or 0.83% from the previous close of ₹1,330.00. During the session, the stock moved within a range of ₹1,316.80 to ₹1,363.00, reflecting moderate market activity following the regulatory update.
Read More: RBI Kept Repo Rate Unchanged: Maintained Policy Stance Neutral.
Aurobindo Pharma’s latest USFDA approval adds to its portfolio in the diabetes treatment segment and supports its presence in the US generics market. While the development provides a potential commercial opportunity, the stock movement indicates a measured market response to the announcement.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
Published on: Apr 8, 2026, 2:18 PM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
